Japanese Pharmaceutical Company Starts Down's Therapy Test

A pharmaceutical company in Japan said it will begin therapeutic testing of a drug it hopes will slow the decline in quality of life for some people with Down's syndrome.

The firm will trial its "Aricept" donepezil hydrochloride drug, commonly used to treat some of the symptoms of Alzheimer's disease, on people between the ages of 15 and 39 who have Down's syndrome.

UN Italians Delight Physically Challenged Lebanese Youths
Ali kneads pizza dough under the watchful eye of Corporal Domenico Magliocca, a UN peacekeeper and head chef teaching handicapped Lebanese the art of preparing the Italian speciality.

Down's is a congenital disorder frequently characterised by diminished mental faculty and physical abnormalities, including distinctive facial features.

It is caused by a chromosome defect and is proportionately more common in people born of older mothers.

From the mid-teens onwards, roughly six percent of people with Down's syndrome lose physical co-ordination, experience sleep disorders and become more withdrawn, a spokesman for pharmaceutical company Eisai said.

Study Finds Boosting Neurotransmitter Could Reverse Down Syndrome
Boosting a neurotransmitter called norepinephrine in Down Syndrome sufferers could help reverse the condition, which is the most common cause of mental retardation in children,

"This testing, if effective, might show that the medication could improve their condition and help improve the quality of their lives," the spokesman said.

It could also ease the burden on their caregivers, he added.

Tumour Suppressor Genes In Down Syndrome Patients Guard Against Breast Cancer
A protein suspected to play a role in Down syndrome (DS) is believed to contribute towards the treatment of breast cancer, according to a study by researchers at the Texas University

Some of the symptoms experienced by people with Down's syndrome are common to some sufferers of Alzheimer's, for which Aricept has long been prescribed.

The testing will initially involve 10 hospitals across Japan, with dozens of people in the affected age group.

Genetics, Not Lack of Exercise, may be a Factor in Health Disparities Among Whites and Blacks in South US
Researchers have said that lack of exercise is not responsible for the health disparities among white and black adults in the South US.

The programme will continue for up to four years, the spokesman said.

The drug is not intended to treat the underlying condition, he said, rather it is hoped it will target some of the symptoms.

Around one in every 830 newborns in the United States has Down's syndrome, according to the National Institutes of Health. This equates to about 250,000 people in the US population, it says.

Source-AFP